NPs will be used in combination with pembrolizumab in patients with locally advanced or metastatic NSCLC with any PD-L1 TPS; the patient is eligible if they have shown almost three months of clinical benefit pursuant to a pembrolizumab-based treatment. Here, CD274 is linked to non-small cell lung carcinoma.